Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL

Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL

Apr 18, 2017
Source URL: https://qa1.novartis.us/us-en/news/media-releases/novartis-car-t-cell-therapy-ctl019-receives-fda-breakthrough-therapy-designation-treatment-adult-patients-rr-dlbcl-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-car-t-cell-therapy-ctl019-receives-fda-breakthrough-therapy-designation-treatment-adult-patients-rr-dlbcl-0